Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when MMED files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsMiniMed expands board to 11, adds Alcon CEO and Medtronic executive as directors
Filed June 29, 2026 · Period ending June 25, 2026 · ~1 min read
Key Changes
-
high
Board expanded from 9 to 11 directors, appointing Alcon CEO David Endicott and Medtronic SVP Linnea Burman effective June 29, 2026. Endicott joins as independent director on Compensation Committee; Burman represents Medtronic affiliate interest.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR → -
high
Burman will receive no board compensation while Medtronic remains a MiniMed affiliate, indicating significant ownership or control relationship between the two companies not detailed in this filing.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR → -
low
2026 annual meeting scheduled for October 9, 2026 (virtual), with August 11 record date. Stockholder proposal deadlines set for July 17 (bylaw nominations/business) and July 26 (Rule 14a-8 proposals).
Item 8.01 — Other Events verify on EDGAR →
Summary
MiniMed expanded its board by two seats and filled them with high-profile healthcare executives: David Endicott, CEO of publicly-traded eye care company Alcon, and Linnea Burman, a 19-year Medtronic veteran currently serving as SVP & President of Neurovascular.
Endicott joins as an independent director and will serve on the Compensation and Talent Committee, bringing leadership experience from Alcon, Hospira, and Allergan. The Burman appointment reveals a material relationship between MiniMed and Medtronic that warrants investor attention.
The filing states Medtronic is currently "an affiliate" of MiniMed and that Burman will receive no board compensation while that affiliation continues. This language suggests Medtronic holds significant ownership or control over MiniMed, though the filing provides no details on the nature or extent of that relationship. Retail holders should seek clarity on Medtronic's stake and influence over MiniMed's strategic direction. The filing also sets routine annual meeting logistics: October 9 virtual meeting with an August 11 record date and July deadlines for stockholder proposals.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Show 3 minor / wording changes
Added in current filing · verify on EDGAR →
The Board has established that MiniMed’s 2026 annual meeting of stockholders (the “2026 Annual Meeting”) will be held virtually on Friday, October 9, 2026 at 9:00 a.m. Pacific Time. The Board has fixed the close of business on Tuesday, August 11, 2026 as the record date for determining the stockholders entitled to notice of, and to vote at, the 2026 Annual Meeting and any adjournment or postponement thereof.
MiniMed announces its 2026 annual stockholder meeting will be held virtually on October 9, 2026 at 9:00 a.m. Pacific Time. The record date for determining voting eligibility is August 11, 2026. This is a routine procedural disclosure required under SEC rules.
Added in current filing · verify on EDGAR →
To be included in the proxy materials for the 2026 Annual Meeting, stockholder proposals submitted in compliance with Rule 14a-8 must be received in writing at the following address, MiniMed Group Inc., Attention: Corporate Secretary, 18000 Devonshire St., Northridge, CA 91325, no later than July 26, 2026, which MiniMed has determined to be a reasonable time before it expects to begin printing and distributing its proxy materials for the 2026 Annual Meeting.
Stockholders wishing to submit proposals for inclusion in the proxy materials under Rule 14a-8 must do so by July 26, 2026. This deadline allows the company reasonable time to prepare and distribute proxy materials before the October meeting.
Added in current filing · verify on EDGAR →
In accordance with the Bylaws, if an eligible stockholder wishes to make a nomination for director, or wishes to introduce any business at the 2026 Annual Meeting, such stockholder must give MiniMed advance notice in accordance with the MiniMed’s Bylaws. To be timely, MiniMed must receive such notice for its 2026 Annual Meeting at the address set forth above no later than July 17, 2026.
Stockholders wishing to nominate directors or introduce business at the meeting outside the proxy materials must provide notice by July 17, 2026, in accordance with the company's bylaws. This is an earlier deadline than the Rule 14a-8 proposal deadline.
Event · Item 5.08 — Shareholder Director Nominations
Procedural 8-K referencing shareholder nomination information disclosed elsewhere; no material business event.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Item 5.08 Shareholder Nominations.
To the extent applicable, the information in
The 8-K references Item 5.08 regarding shareholder nominations but provides no substantive disclosure in the body text. The sentence appears incomplete, suggesting the relevant information is incorporated by reference from another document or filing. This is a procedural filing with no material business impact.
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On June 25, 2026, the Board of Directors (the “Board”) of MiniMed Group, Inc. (“MiniMed”) increased the size of the Board from nine to 11 and appointed David Endicott and Linnea Burman to serve as a directors of the Board to fill the resulting vacancies, effective June 29, 2026.
MiniMed expanded its board by two seats and filled them with David Endicott (CEO of Alcon Inc.) and Linnea Burman (SVP & President, Neurovascular at Medtronic). Endicott will serve as a class I director with a term expiring at the 2026 annual meeting and join the Compensation and Talent Committee. Burman will serve as a class II director with a term expiring at the 2027 annual meeting.
Added in current filing · verify on EDGAR →
Mr. Endicott currently serves as Chief Executive Officer of Alcon, Inc. (NYSE: ALC; SWX: ALC), an eye care company, and has served as a member of Alcon’s board of directors since 2019. Prior to joining Alcon, Inc., Mr. Endicott held senior leadership roles at various healthcare organizations, including as Chief Executive Officer and Chief Operating Officer of Alcon Laboratories, Inc., President of Hospira Infusion Systems at Hospira, Inc., and various commercial and regional leadership roles at Allergan, Inc. ... The Board has determined that Mr. Endicott is “independent” in accordance with the rules of The Nasdaq Stock Market LLC, the Securities and Exchange Commission (the “SEC”) and MiniMed’s corporate governance guidelines.
Endicott brings extensive healthcare leadership experience as the current CEO of publicly-traded Alcon and prior executive roles at Hospira and Allergan. The board has determined he qualifies as an independent director under Nasdaq and SEC rules, with no disclosed related-party transactions.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 6, 2026 · How we verify